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Vascular endothelial growth factor (VEGF) is a potent mitogen for tumor angiogenesis. Clinically, VEGF 
detection in human blood can be expected to be used in the very near future for cancer screening, 
prognosis, monitoring of therapy and diagnosis. VEGF has been identified as the target for the 
treatment of cancer. Though prokaryotic expression of VEGF has been done, the solubilization and 
purification is time consuming and empirical. In this study, VEGF165 and VEGF121 were cloned into 
pGEX-4T-1 vector, and GST-VEGF fusion proteins were expressed in Escherichia coli at 37°C. The 
inclusion bodies of GST-VEGF fusion proteins were solubilized with N-Lauroylsarcosine (sarkosyl). 
Briefly, the cell suspension with inclusion body was added with sarkosyl at a final concentration of 
1.5%. After the disruption of cells, the clarified supernatant containing sarkosyl was added with Triton 
X-100 at a final concentration of 3%. The GST-VEGFs were purified by affinity chromatography on 
glutathione Sepharose 4B. The overall yield was approximately 10 – 12 mg/l cell culture. The binding 
assay showed that the GST-VEGF165 binds to VEGF receptor in a dose dependent manner. The current 
work provides a novel procedure for solubilization and purification of GST-VEGF fusion proteins, and 
no laborious procedures for separation of inclusion bodies and renaturation were needed.  
 





Vascular endothelial growth factor (VEGF), also known as 
vascular permealility factor, was first described by Senger 
and Leung (Senger et al., 1983; Leung et al., 1989). 
VEGF is a disulphide-linked homodimer protein of 34-42 
KDa, and a potent and specific endothelial cell mitogen 
involved in the induction of angiogenesis, that is the 
growth of new blood vessels. VEGF is synthesized in res-
ponse to hypoxia and other stimuli. Alternative splicing of 
a single VEGF mRNA renders four main VEGF isoforms, 
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1991). VEGF121 and VEGF165 are soluble isoforms of 
VEGF, while VEGF189 and VEGF206 are associated with 
the extracellular matrix. The predominant form of VEGF is 
VEGF165 (Ferrara and Henzel, 1989). VEGF is expressed 
and secreted by almost all solid tumors. 
VEGF is a potential and unique tumor marker in tumor 
diagnosis and prognosis. Current data show that: (i) 
VEGF can be detected in the blood by enzyme-linked 
immunosorbent assay (ELISA) and in tissues by immu-
nohistochemistry; (ii) VEGF detections could be used for 
determining the risk of developing cancer, screening for 
early detection and evaluating the prognosis of cancer, 
monitoring of cancer therapies especially chemotherapy, 





benign from malignant diseases (Poon et al., 2001; Pang 
and Poon, 2006; Kuroi and Toi, 2001). VEGF has also 
been identified as targets for clinical intervention of 
cancer patients. Bevacizumab (avastin), a humanized 
mono-clonal antibody, that binds and inhibits VEGF, has 
been approved by the Food and Drug Administration 
(FDA) of the USA in 2004 for the treatment of various 
cancers. Many other VEGF inhibitors are now been deve-
loped for treatment of cancers (Hurwitz et al., 2004a, b).  
As VEGF is becoming more and more important in both 
clinical and basic research, a simple and time-saving 
procedure for expression and purification of recombinant 
VEGF is needed. Previously, VEGF had been expressed 
from bacteria (Siemeister et al., 1996). Although expres-
sion as inclusion bodies can often be advantageous for 
yield, the procedures for separation, washing and solubi-
lization of inclusion bodies and renaturation of the 
recombinant protein are often time consuming and empi-
rical (Siemeister et al., 1996; Cabrita and Bottomley, 
2004). The problems of solubility of some GST-fusion 
proteins, for example, CMPK, EcR and USP were 
partially overcome by the use of the alkyl anionic 
detergent, sarkosyl (Frangioni and Neel, 1993; Elke et al., 
1997). However, no literature shows whether VEGF165 
and VEGF121 can be expressed as GST fusion proteins 
and solubilized with sarkosyl. In the present study, we 
describe a novel, convenient and effective procedure to 
solubilize and purify the inclusion bodies of VEGF165 and 
VEGF121 from Escherichia coli and it could serve as an 
easily available source of recombinant VEGF for animal 
immunization and other research purposes.  
 
 
MATERIALS AND METHODS 
 
Construction of expression plasmids 
 
VEGF165 and VEGF121 gene fragments without signal peptide se-
quences were amplified from human placenta cDNA (Clontech, 
Mountain View CA, USA) by PCR. The cDNA fragments encoding 
amino acids 2 - 165 of VEGF165 and encoding amino acid 2 - 121 of 
VEGF121 were then cloned into pGEX-4T-1 prokaryotic expression 
vector with the cloning sites upstream of EcoRI and down stream of 
Not I. The recombinant DNA encodes amino acids 2 - 165 of native 
human VEGF165 and amino acids 2 - 121 of native human VEGF121 
(Semeister et al., 1996; Weindel et al., 1992). The fidelity of the 
recombinant DNAs were finally confirmed by DNA sequencing 
analysis. The expression plasmids then were transformed to E. coli 
strain BL21(DE3)pLysS. Recombinant clones were screened with 
different concentrations of IPTG at different time points. One clone 
with highest expression of proteins was selected from pGEX-4T-
1/VEGF165 and pGEX-4T-1/VEGF121 respectively.  
 
 
Expression, solubilization and purification of GST-VEGFs 
 
The expression, solubilization and purification of the GST-VEGF 
fusion protein were performed essentially as described by Frangioni 
and Neel (1993) with the following modifications. A single colony of 
E. coli strain BL21(DE3)pLysS transformed with the plasmid of 
pGEX-4T-1/VEGF165 or pGEX-4T-1/VEGF121 was grown at 37°C 
overnight in 50 ml of LB. 1 ml of the overnight culture was added to  
50 ml of fresh LB (1:50 dilution) and grown  at  37°C to  an  OD600 =  




0.6-0.8. 100 g/ml ampicillin was added to the culture. Bacterial 
expression was induced by the addition of 1mM IPTG; the culture 
was further incubated at 37°C for 2 - 3 h. Bacteria were collected by 
centrifugation, washed with STE buffer (10 mM Tris-HCl, pH 
8.0;150 mM sodium chloride; and 1 mM EDTA) and pelleted by 
centrifugation. The pelleted bacteria were then resuspended in lysis 
buffer (STE + lysozyme 100 g/ml) and incubated for 15 min on ice 
followed by the addition of final concentration of 5 mM DTT and 15 
mM PMSF. Sarkosyl (Sigma-Aldrich, St. Louis MO, USA) was 
added to a final concentration of 1.5% (W/V). After vortexing for 10 
seconds, bacteria were disrupted by sonication for 30 s on ice 3 
times followed by centrifugation at 13,000 rpm/min for 10 min. The 
supernatant was transferred to a new tube and treated with Triton 
X-100 at a final concentration of 3%.  
The GST-VEGF fusion proteins were covalently absorbed on 
glutathione Sepharose 4B. Briefly, the glutathione Sepharose 4B 
(GE Healthcare, Life Sciences Piscataway, NJ, USA) was equili-
brated in PBS and 1 ml of the beads were incubated with cell 
lysates prepared as previously described overnight at 4°C with sha-
king. The GST-VEGF fusion proteins were eluted with buffer con-
taining 10 mM reduced gluthathione. Concentrated, the protein 
samples were stored in glycerol containing Tris-HCl at a final 
concentration of 10% (v/v) and protein solution was kept at either 
4°C for short or -80°C for long storage. 
All protein samples were analyzed by 10% SDS-PAGE and 





Recombinant extracellular domain of human VEGF receptor (rh-
sFlt-1, Sigma Aldrich, St. Louis, MO, USA) was coated onto Nunc 
96-well-microplate (0.25 g/well). After addition of increased 
concentration of GST-VEGF165, wells were incubated with horse-
radish peroxidase (HRP) labeled VEGF polyclonal antibody. For 
control, GST-VEGF165 was replaced by GST and incubated with 
HRP-labelled GST polyclonal antibody.  
  
 
RESULTS AND DISCUSSION 
 
Expression of VEGFs as GST fusion protein 
 
Expression of GST-VEGF fusion proteins is under the 
control of the tac promoter, which is induced by IPTG 
(Figure 1a). Prominent protein bands corresponding to a 
calculated molecular weight of approximately 48 kDa 
(GST-VEGF165), 42 kDa (GST-VEGF121) and 26 kDa 
(GST) were detected. No significant differences were 
found in the fusion protein amount expressed by incu-
bation for 2 - 3 h. A GST-PC protein was used for positive 
control of expression, as it is the first time to express 
GST-VEGF165 and GST-VEGF121 (Figure 1b).  
 
 
Solubilization and purification of GST-VEGF with 
sarkosyl 
 
To solubilize and purify the GST-VEGF165 and GST VEG 
F121 fusion proteins, 1.5% sarkosyl, an alkyl anionic 
detergent, was used for the procedure. The purity of the 
final products was more than 95% based on evaluation of 
Coomassie-stained gels and the overall yield was  around  






Figure 1a. The schematic diagram of the recombinant plasmid pGEX-4T-






Figure 1b. 10% SDS-PAGE analysis of bacteria expressed GST-VEGF165 and GST-
VEGF121. M: Protein Marker. Lane 1: E. coli/GST lysates without IPTG induction for 3 h; 
Lanes 2 and 3: E. coli/GST lysates with IPTG induction for 2 and 3 h respectively; Lane 4: 
E. coli/GST-PC lysates without IPTG induction for 3 h; Lanes 5 and 6: E. coli/GST-PC 
lysates with IPTG induction for 2 and 3 h respectively; Lane 7: E. coli/GST-VEGF165 lysates 
without IPTG induction for 3 h; Lanes 8 and 9: E. coli/GST-VEGF165 lysates with IPTG 
induction for 2 and 3 hours respectively; Lane 10: E. coli/GST-VEGF121 lysates without 
IPTG induction for 3 hours; Lanes 11 and 12: E. coli/GST-VEGF121 lysates with IPTG 
induction for 2 - 3 h respectively. Arrows show the GST-VEGF165 (up arrow), GST-VEGF121 
(middle arrow) and GST (low arrow) at 48, 42 and 26 kDa respectively.  
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Figure 2. Purification of GST-VEGF fusion proteins analyzed by 10% SDS-PAGE. Lane 1; 
Bacterial lysates with unpurified GST-VEGF165 (A) or GST-VEGF121 (B). Lane 2. Purified 





10-12 mg/l bacteria culture (Figure 2). All VEGF isoforms 
are covalently linked homodimers with a glycosylation 
site at Asn74, which is not required for VEGF biological 
activity. The molecular weight of VEGF165 and VEGF121 is 
22 and 16 kDa under reduced conditions. The GST is a 
26 kDa protein. The sizes of GST-VEGF165 and GST-
VEGF121 are estimated to be 48 and 42 kDa respectively 
(Siemeister et al., 1996).  
The procedure for purification of VEGF expressed from 
E. coli has the following steps generally: (1) separation 
and washing of inclusion body; (2) protein solubilization 
and renaturation; and (3) purification. The procedure is 
complicated, time-consuming and empirical (Siemeister 
et al., 1996; Lilie et al., 1998). We introduce a novel 
procedure here to purify GST-VEGF, a method that with 
only one step, the solubilization with Sarkosyl, was 
needed, and to skip the complicated procedures of sepa-
ration, washing and renaturation of inclusion bodies.  
 
 
Binding activity of GST-VEGF165 to rh-sFlt-1 
 
Binding ability of GST-VEGF165 expressed in E. coli to 
recombinant human extracellular domain VEGF receptor 
(rh-sFlt-1) which was expressed from baculovirus, was 
studied by a sandwich-like assay. The affinity constant 
was approximately 106 mol/l (Figure 3). Frangioni and 
Neel (1993) reported that the enzymatic activity of tyro-
sine phosphatase 1B was maintained during the proce-
dure of sarkosyl solubilization and purification. The hygro-
mycin B phosphotransferase with biological activity was 
solubilized and purified from prokaryotic expression by 
sarkosyl (Zhuo et al., 2005). Our data show that GST-
VEGF165 binds to soluble extracellular domain Flt-1 in a 
dose-dependent manner. 
The interaction of VEGF with its signaling tyrosine 
kinas receptors is a very important biological function. 
VEGF binds VEGF receptor 1 (VEGFR-1) and receptor 
2(VEGFR-2) at different sites. The main cluster of VEGF 
amino acids that bind VEGFR-1 is located at one end of 
the VEGF monomer and the main cluster of VEGF amino 
acids that binds to VEGFR-2 is located at the opposite 
pole of the VEGF monomer. 3 acidic residues, Asp63, 
Glu64 and Glu67 in exon 3 are essential for binding to 
VEGFR-1, and 3 basic residues, Arg82, Lys84 and His86, 
in exon 4 are essential for binding to VEGFR-2 (Neufeld 





In conclusion, we have established a novel and efficient 
procedure to express and purify biologically active GST-
VEGF165 and GST-VEGF121 from E. coli /pGEX-4T-1 
fusion system. Sarkosyl is an alkyl anionic detergent and 
can be used  for  solubilization  and  renaturation  of  bac- 






Figure 3. Binding activity of GST-VEGF165 to VEGF receptor. 
Recombinant human fusion VEGF165 binds to VEGF receptor, 




terial expressed inclusion bodies of VEGF. With sarkosyl, 
overall yield of GST-VEGF was up to 12 mg/l cell culture, 
and two laborious steps; the separation, washing and 
solubilization of inclusion body and renaturation of fusion 
proteins were skipped. Therefore, the novel procedure 
reported here can not only produce high amounts of 
VEGF fusion protein, which could be used for animal im-
munization and other research purpose, but also make 
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